Loading the section…
The price of Taysha Gene Therapies, Inc. (TSHA) on October 9, 2026 is 4.49 USD, +1.35% on the day. Over 52 weeks the stock traded between 3.69 USD and 7.30 USD; the price now sits 22% of the way up that range. Over the past year the price changed by -11.26%. Market capitalization is 1.29 billion USD, rank 35 among 128 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): −11.09 %
Taysha Gene Therapies, Inc. trades on Nasdaq under the ticker TSHA. The company belongs to the Health care sector. The trading history on this page starts on 24 September 2020.
Over the past 52 weeks TSHA has traded between 3.69 $ and 7.30 $. As of 9 October 2026 the price stood 22.10 % of the way from the 52-week low to the high.
Over one year TSHA shares fell 11.26 %; over six months they were unchanged. Volatility over 90 days is 61.63 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 173, above the sector median of 4.0. Price to book is 6.1, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 4.42 | 4.57 | 4.36 | 4.49 | 5M |
| 8 October 2026 | 4.37 | 4.46 | 4.33 | 4.43 | 4M |
| 7 October 2026 | 4.33 | 4.46 | 4.26 | 4.43 | 4M |
| 6 October 2026 | 4.51 | 4.57 | 4.26 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
No events for this security recently.
Address:3000 PEGASUS PARK DRIVE SUITE 1430, DALLAS, TX, 75247, US
Taysha Gene Therapies, Inc. reported revenue of 7M $ and a net loss of 130M $ over the last four quarters. Net margin is −1,738.40 %. Revenue changed by +3.42 % year over year. Earnings per share are −0.38 $. Market capitalisation is 1.3B $.
TSHA has a return on equity of −61.28 %, below the sector median of −41.68 %. Return on assets is −43.24 %, below the sector median of −32.11 %. Operating margin is −1,774.37 %, below the sector median of −26.84 %.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 110.42 | +0.53 % | 253M |
| BIIBBiogen Inc. | 225.71 | +3.33 % | 227M |
| KODKodiak Sciences Inc | 99.87 | +5.95 % | 219M |
| 4.39 |
| 5M |
| 5 October 2026 | 4.64 | 4.64 | 4.37 | 4.49 | 5M |
| 2 October 2026 | 4.80 | 4.86 | 4.63 | 4.63 | 3M |
| 1 October 2026 | 4.86 | 4.94 | 4.73 | 4.74 | 4M |
| 30 September 2026 | 5.03 | 5.03 | 4.82 | 4.87 | 4M |
| 29 September 2026 | 4.97 | 5.03 | 4.80 | 4.99 | 7M |
| 28 September 2026 | 4.64 | 5.06 | 4.56 | 4.99 | 6M |
| 25 September 2026 | 4.88 | 4.88 | 4.67 | 4.67 | 5M |
| 24 September 2026 | 4.88 | 4.90 | 4.66 | 4.79 | 6M |
| 23 September 2026 | 5.11 | 5.14 | 4.88 | 4.91 | 6M |
| 22 September 2026 | 5.11 | 5.22 | 5.08 | 5.16 | 2M |
| 21 September 2026 | 5.07 | 5.12 | 5.00 | 5.04 | 2M |
| 18 September 2026 | 5.16 | 5.28 | 4.96 | 5.02 | 9M |
| 17 September 2026 | 5.25 | 5.46 | 5.05 | 5.16 | 4M |
| 16 September 2026 | 5.08 | 5.14 | 4.98 | 5.07 | 4M |
| 15 September 2026 | 5.00 | 5.19 | 4.90 | 5.06 | 5M |
| 14 September 2026 | 5.00 | 5.12 | 4.98 | 5.01 | 7M |